Celcuity reports Q4 EPS (73c), consensus ($1.01)

Cash, cash equivalents and short-term investments were $441.5M at the end of fiscal year 2025 and are expected to finance our operations through 2027. “We expect this year to be a transformative one for Celcuity (CELC). We plan to release topline results from the PIK3CA mutant cohort of our Phase 3 VIKTORIA-1 study in the second quarter of 2026, which, if positive, could potentially advance the standard-of-care second line therapy for a significant number of patients with HR+/HER2- advanced breast cancer,” said Brian Sullivan, CEO and co-founder of Celcuity. “Additionally, our efforts remain on track to launch gedatolisib commercially in anticipation of its potential FDA approval in the third quarter of 2026.”